Skip to main content
Biocorp logo

Biocorp — Investor Relations & Filings

Ticker · ALCOR ISIN · FR0012788065 LEI · 969500TKUAME6031UQ32 PA Manufacturing
Open in API
Filings indexed 235 across all filing types
Latest filing 2024-01-25 Regulatory Filings
Country FR France
Listing PA ALCOR

About Biocorp

https://biocorpsys.com

Biocorp designs, develops, and manufactures medical devices and drug delivery systems for the pharmaceutical industry. The company specializes in combining precision engineering with connected technologies to improve patient treatment adherence and outcomes. Its portfolio includes both connected and non-connected devices, such as smart caps for inhalers (Inspair), pen injectors, and systems for drug reconstitution and safety. Biocorp manages the entire value chain, from research and development to manufacturing and final packaging, leveraging its expertise in plastics processing and advanced technological innovation. Since October 2023, Biocorp has been a subsidiary of Novo Nordisk.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release dated January 25, 2023, announcing that BIOCORP received 510(k) clearance from the US FDA for its SoloSmart device, which connects to Sanofi's insulin pens. This type of announcement, detailing a significant regulatory milestone (FDA clearance) and its commercial implications, is typically classified as a general regulatory announcement or a news release that doesn't fit the specific financial report categories (like 10-K, ER, or IR). Since it is a specific announcement about a regulatory event (FDA clearance) but not a formal SEC filing or a financial report, it best fits the 'Regulatory Filings' (RNS) category as a general regulatory announcement, or potentially 'LTR' if viewed as a legal/regulatory update, but RNS is the broader fallback for non-financial regulatory news. Given the context of a press release announcing a major regulatory approval, RNS is the most appropriate general classification.
2024-01-25 French
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is a press release announcing that BIOCORP obtained 510(k) FDA clearance for its SoloSmart device. This type of announcement, detailing a specific regulatory milestone (FDA clearance) and its implications, does not fit neatly into the standard financial reporting categories like 10-K, ER, or IR. It is a specific, material event announcement. Since it is not a standard financial report, nor a management change, dividend notice, or capital activity, it best fits the general 'Regulatory Filings' category (RNS) as a significant, non-standard regulatory update, or potentially 'LTR' if viewed as a regulatory approval process update, but RNS is the broader fallback for miscellaneous regulatory news. Given the context of a press release announcing a specific regulatory achievement (FDA clearance), RNS is the most appropriate general classification for non-standard regulatory news.
2024-01-25 English
Franchissement de seuils
Major Shareholding Notification Classification · 1% confidence The document is titled "Déclaration de franchissement de seuils (article L. 233-7 du code de commerce)" which translates to 'Declaration of crossing thresholds (Article L. 233-7 of the Commercial Code)'. This type of filing in France (often reported to the AMF) concerns changes in significant share ownership, where an entity crosses specific percentage thresholds of capital or voting rights. This directly corresponds to the definition of Major Shareholding Notification (MRQ), which covers 'Notification of changes in significant share ownership levels (crossing thresholds)'. The content details Novo Nordisk Region Europe A/S crossing the 90% threshold of BIOCORP PRODUCTION's capital and voting rights.
2023-10-03 French
Acquisition ou cession des actions de l'émetteur / Information relative au contrat de liquidité
Share Issue/Capital Change Classification · 1% confidence The document announces the termination of a liquidity contract ('contrat de liquidité') between BIOCORP and the brokerage firm Gilbert Dupont, effective September 28, 2023. It details the remaining assets (shares and cash) in the liquidity account as of the termination date and compares them to previous balances (June 30, 2023, and February 3, 2020). This type of announcement concerns financial arrangements, capital management, or specific market-making activities, but it does not fit neatly into the primary categories like 10-K, ER, or IR. It is a specific regulatory or market-related disclosure. Since it is not a dividend notice (DIV), capital change (SHA), or director dealing (DIRS), and it is a specific announcement, the most appropriate general category for specific, non-standard regulatory disclosures that affect market operations is 'Regulatory Filings' (RNS), as it is a formal notice to the market about a change in financial arrangement.
2023-10-02 French
Communiqués publiés en période d'offre publique d'acquisition / OPA Autres communiqués
Delisting Announcement Classification · 1% confidence The document is a formal press release dated October 2, 2023, detailing the implementation of a mandatory squeeze-out (retrait obligatoire) of Biocorp Production shares following a successful public tender offer (Offre Publique d'Achat) initiated by Novo Nordisk Region Europe A/S. It explicitly references compliance with the General Regulation of the Autorité des marchés financiers (AMF) and specifies the compensation amount (€35 per share) and the implementation date (October 11, 2023). This action—the compulsory acquisition of remaining minority shares after a takeover—is a specific corporate action related to capital structure changes following a successful M&A event. While it relates to the aftermath of a takeover (TAR), the core subject is the final step of delisting/cancellation of minority holdings post-acquisition, which often results in the stock being removed from the exchange. However, the document focuses on the mandatory buy-out mechanism itself, which is a significant capital/financing event following a transaction. Given the options, this is most closely related to a Capital/Financing Update (CAP) as it finalizes the capital structure post-takeover, or potentially a Delisting Announcement (DLST) as the squeeze-out usually precedes delisting. Since the text focuses heavily on the mechanics, price, and regulatory compliance of the mandatory buy-out (a financing/capital restructuring step), CAP is a strong fit. If the document were solely the notice of delisting, DLST would be better. Since it details the mandatory purchase price and process following the acquisition, CAP is the most appropriate classification among the choices for this specific post-M&A capital event.
2023-10-02 French
Communiqués publiés en période d'offre publique d'acquisition / OPA Modalités de mise à disposition du projet de note d'information ou du projet de note en réponse
M&A Activity Classification · 1% confidence The document is a press release announcing the availability of an information memorandum (Note d'Information) regarding a public tender offer (Offre Publique d'Achat) by Novo Nordisk for Biocorp shares. It explicitly states that the information has been filed with the AMF and is now available to the public, which aligns with the definition of a Report Publication Announcement (RPA) for M&A-related documentation.
2023-09-06 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.